Renaissance Capital logo

Forte Biosciences (Tocagen) Priced, Nasdaq: FBRX

Developing a combination gene therapy treatment for brain cancer.

Industry: Health Care

First Day Return: +24.5%

We are a clinical-stage, cancer-selective gene therapy company focused on developing first-in-class, broadly-applicable product candidates designed to activate a patient’s immune system against their own cancer from within. Our cancer-selective gene therapy platform is built on retroviral replicating vectors, or RRVs, which are designed to selectively deliver therapeutic genes into the DNA of cancer cells. Our gene therapy approach is designed to fight cancer through immunotherapeutic mechanisms of action without the autoimmune toxicities commonly experienced with other immunotherapies. Our founding vision is "No One Should Die Of Cancer" because we believe the immune system can be safely activated to fight the patient’s cancer.
IPO Data
IPO Date 04/12/2017
Offer Price IPO Intelligence Only
Price Range IPO Intelligence Only
Offer Shares (mm) IPO Intelligence Only
Deal Size ($mm) $85
Lock-Up Date IPO Intelligence Only
Street Research IPO Intelligence Only
Underwriters
IPO Intelligence Only
Company Data
Headquarters San Diego, CA, United States
Founded 2007
Employees at IPO 61
Website www.tocagen.com

Forte Biosciences (Tocagen) (FBRX) Performance

Created with Highcharts 10.3.2Chart context menuFBRX vs. IPO Index (IPOUSA)Jul 2017Jan 2018Jul 2018Jan 2019Jul 2019Jan 2020Jul 2020Jan 2021Jul 2021Jan 2022Jul 2022Jan 2023Jul 2023Jan 2024Jul 2024Jan 2025Jul 20250%+ 100%+ 200%+ 300%-100%View 5 days5dView 1 month1mView 3 months3mView year to dateYTDView 1 year1yView allAllRenaissance IPO IndexOur ETF tracks the IPO Index